12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Simeprevir: Additional Phase III data

Medivir reported subgroup data from the double-blind, placebo-controlled, international Phase III QUEST-1 trial in 394 treatment-naive patients with HCV genotype 1 infection evaluating once-daily 150 mg oral simeprevir for 12 weeks plus Pegasys peginterferon alfa-2a and Copegus ribavirin for 24 or 48 weeks. In patients treated with simeprevir, rates of SVR 12 weeks after the end of treatment were 94% in patients with the CC genotype of the interleukin-28B...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >